Viewing Study NCT03002103


Ignite Creation Date: 2025-12-24 @ 7:45 PM
Ignite Modification Date: 2026-02-21 @ 10:11 PM
Study NCT ID: NCT03002103
Status: SUSPENDED
Last Update Posted: 2023-04-26
First Post: 2016-12-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Trial Evaluating the Efficacy and Safety of EndoTAGĀ®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Sponsor: SynCore Biotechnology Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module